Article
Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.
Journal of biomolecular structure & dynamics - 1 Aug 2022
Boonma Thitiya, Nutho Bodee, Darai Nitchakan, Rungrotmongkol Thanyada, Nunthaboot Nadtanet
Abstract excerpt
Hepatitis C virus (HCV) NS3/4A serine protease is a promising drug target for the discovery of anti-HCV drugs. However, its amino acid mutations, particularly A156T, commonly lead to rapid emergence of drug resistance. Paritaprevir and glecaprevir, the newly FDA-approved HCV drugs, exhibit distinct resistance profiles against the A156T mutation of HCV NS3/4A serine protease. To illustrate their different...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.